 |
 |
|
|
RESÚMENES NOVIEMBRE 2004 |
Psychotic Disorders & Antipsychotics
(Requiere estar conectado a internet. Haga un click en la
información del journal)
Holger J. Sørensen, Erik L. Mortensen, June M. Reinisch, Sarnoff A.
Mednick
The British Journal of Psychiatry (2004) 185: 366-371
Brain Anatomy in Adults With Velocardiofacial Syndrome With and
Without Schizophrenia
Preliminary Results of a Structural Magnetic Resonance Imaging
Study
Therese
van Amelsvoort, Eileen Daly, Jayne Henry, Dene Robertson, Virginia Ng, Michael
Owen, Kieran C. Murphy, Declan G. M. Murphy
Arch Gen Psychiatry. 2004;61:1085-1096
Raphael J. Braga,
Georgios Petrides and Ivan Figueira
Comprehensive Psychiatry Volume 45, Issue 6 ,
November-December 2004, Pages 460-468
Effect of repeated treatment with olanzapine or olanzapine plus
fluoxetine on tyrosine hydroxylase in the rat locus coeruleus
Ordway GA, Szebeni K.
International Journal of Neuropsychopharmacology
2004;7(3):321-327
Olanzapine increases plasma ghrelin level in patients with schizophrenia
Murashita M, Kusumi I, Inoue T, et al.
Psychoneuroendocrinology 2005;30(1):106-110
Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia
Harvey AT, Flockhart D, Gorski JC, et al.
J Clin Pharmacol 2004;44(10):1173-1184
Attila Sipos, Finn Rasmussen, Glynn Harrison, Per
Tynelius, Glyn Lewis, David A Leon, David Gunnell
BMJ 2004;329:1070 (6 November)
New nomenclature for drug-induced movement disorders including tardive
dyskinesia
Chouinard G.
Journal of Clinical Psychiatry 2004;65(SUPPL. 9):9-15
Gury C.
Encephale 2004;30(4):382-391
Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features
and management
Haddad PM, Wieck A.
Quality of Life Outcomes of Risperidone, Olanzapine, and Typical
Antipsychotics Among Schizophrenia Patients Treated in Routine Clinical
Practice: A Naturalistic Comparative Study
Ritsner, Michael ; Gibel, Anatoly ; Perelroyzen, Galina ;
Kurs, Rena ; Jabarin, Mahmoud ; Ratner, Yael
Journal of Clinical
Psychopharmacology. 24(6):582-591, December 2004
Venlafaxine for the Treatment of Depressive Episode During the Course of
Schizophrenia
Mazeh, Doron; Shahal, Baruch; Saraf, Roni; Melamed, Yuval
Journal of Clinical
Psychopharmacology. 24(6):653-655, December 2004
Haloperidol Half-life After Chronic Dosing.
de Leon, Jose ; Diaz, Francisco J. ; Wedlund, Peter ;
Josiassen, Richard C. ; Cooper, Thomas B; Simpson, George M
Journal
of Clinical Psychopharmacology. 24(6):656-660, December 2004
Temperament types
are associated with weak self-construct, elevated distress and emotion-oriented
coping in schizophrenia: evidence for a complex vulnerability marker?
Michael Ritsner and
Ehud Susser
Psychiatry Research. Volume 128, Issue 3, 30 October
2004, Pages 219-228
Association of
diabetes with dyskinesia in older psychosis patients
Michael P. Caligiuri
and Dilip V. Jeste
Psychopharmacology 2004; Volume 176, Numbers
3-4: 281 - 286
A novel
antipsychotic, perospirone, has antiserotonergic and antidopaminergic effects
in human brain: findings from neuroendocrine challenge tests
M. Iwakawa,
T. Terao, A. Soya, H. Kojima, Y. Inoue, N. Ueda,
R. Yoshimura and J. Nakamura
Psychopharmacology 2004; Volume 176, Numbers
3-4: 407 - 411
Volume reduction
of the amygdala in patients with schizophrenia: a magnetic resonance imaging
study
Lisha Niu, Mie
Matsui, Shi-Yu Zhou, Hirofumi Hagino, Tsutomu Takahashi, Eiichi Yoneyama,
Yasuhiro Kawasaki, Michio Suzuki, Hikaru Seto, Taketoshi Ono and Masayoshi
Kurachi
Psychiatry Research: Neuroimaging. Volume 132, Issue 1, 15 November 2004, Pages
41-51
Prevalence of Hyperprolactinemia in Schizophrenia:
Association With Typical and Atypical Antipsychotic Treatment
Julie Montgomery,
Elizabeth Winterbottom, Meera Jessani, Eva Kohegyi, Janice Fulmer, Bette
Seamonds, and Richard C. Josiassen
J Clin Psychiatry 2004;65:1491-1498
Neural synchrony
indexes disordered perception and cognition in schizophrenia (electroencephalogram
|
Kevin M. Spencer, Paul G. Nestor, Ruth Perlmutter, Margaret A.
Niznikiewicz, Meredith C. Klump, Melissa Frumin, Martha E. Shenton, and Robert
W. McCarley
Proc.
Natl. Acad. Sci. USA, 10.1073/pnas.0406074101
Efficacy and
safety of long-acting risperidone in stable patients with schizoaffective
disorder
Robert Lasser,
Cynthia A. Bossie, Georges Gharabawi, Marielle Eerdekens and Henry A. Nasrallah
Journal of Affective Disorders. Volume 83, Issues 2-3,
December 2004, Pages 263-275
Schizophrenia,
epigenetics and ligand-activated nuclear receptors: a framework for chromatin
therapeutics
Rajiv P. Sharma
Schizophrenia Research. Volume 72, Issues 2-3, 1 January 2005, Pages
79-90
A forced
five-dimensional factor analysis and concurrent validity of the Positive and
Negative Syndrome Scale in Mexican schizophrenic patients
A. Fresán, C. De la
Fuente-Sandoval, C. Loyzaga, M. García-Anaya, N. Meyenberg, H. Nicolini and R.
Apiquian
Schizophrenia Research. Volume 72, Issues 2-3, 1 January 2005, Pages
123-129
Francisco J. Diaz,
Jose de Leon, Richard C. Josiassen, Thomas B. Cooper and George M. Simpson
Schizophrenia Research. Volume 72, Issues 2-3, 1 January 2005, Pages
131-135
James T. Chok,
Thomas R. Kwapil and Angela Scheuermann
Schizophrenia Research. Volume 72, Issues 2-3, 1 January 2005, Pages
205-214
Harri J. Tuominen,
Jari Tiihonen and Kristian Wahlbeck
Schizophrenia Research. Volume 72, Issues 2-3, 1 January 2005, Pages
225-234
Long-acting
risperidone vs. placebo in the treatment of hospital inpatients with
schizophrenia
John
Lauriello, Joseph P. McEvoy, Stephen Rodriguez, Cynthia A. Bossie and Robert A.
Lasser
Schizophrenia Research. Volume 72, Issues 2-3, 1 January 2005, Pages
249-258
Serge A. Mitelman,
Lina Shihabuddin, Adam M. Brickman, Erin A. Hazlett and Monte S. Buchsbaum
Schizophrenia
Research. Volume 72, Issues 2-3, 1 January 2005, Pages 91-108